Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community

BMC Medicine

Volumn 6, Issue , 2008, Pages

  Chris, J A Chris ^a,b   Schneider Lindner, Verena ^a,b   Brassard, Paul ^a,b   Suissa, Samy ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; METICILLIN; PREDNISONE;

ADULT; AGE; ANAMNESIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; COHORT ANALYSIS; COMMUNITY ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENERAL PRACTICE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; POPULATION RESEARCH; PREVALENCE; RISK ASSESSMENT; STAPHYLOCOCCUS INFECTION; COMMUNICABLE DISEASE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PENICILLIN RESISTANCE; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS;

COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 40349103650     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-6-2     Document Type: Article

References (32)

1. Grundmann H Aires-de-Sousa M Boyce J Tiemersma E: Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006, 368:874-885. 10.1016/ S0140-6736(06)68853-3 16950365
2. Zetola N Francis JS Nuermberger EL Bishai WR; Community-acquired meticillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005, 5:275-286. 10.1016/S1473-3099(05)70112-2 15854883
3. Robinson DA Kearns AM Holmes A Morrison D Grundmann H Edwards G O'Brien FG Tenover FC McDougal LK Monk AB Enright MC: Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005, 365:1256-1258. 10.1016/ S0140-6736(05)74814-5 15811459
4. Fridkin SK Hageman JC Morrison M Sanza LT Como-Sabetti K Jernigan JA Harriman K Harrison LH Lynfield R Farley MM: Active Bacterial Core Surveillance Program of the Emerging Infections Program Network Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444. 10.1056/NEJMoa043252 15814879
5. Moran GJ Amii RN Abrahamian FM Talan DA: Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005, 11:928-930. 15963289
6. Maltezou HC Giamarellou H: Community-acquired methicillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 2006, 27:87-96. 10.1016/j.ijantimicag.2005.11.004 16423509
7. Francis JS Doherty MC Lopatin U Johnston CP Sinha G Ross T Cai M Hansel NN Perl T Ticehurst JR Carroll K Thomas DL Nuermberger E Bartlett JG: Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005, 40:100-107. 10.1086/427148 15614698
8. Gilbert M MacDonald J Gregson D Siushansian J Zhang K Elsayed S Laupland K Louie T Hope K Mulvey M Gillespie J Nielsen D Wheeler V Louie M Honish A Keays G Conly J: Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration. CMAJ 2006, 175:149-154. 1490001 16804118
9. Miller LG Quan C Shay A Mostafaie K Bharadwa K Tan N Matayoshi K Cronin J Tan J Tagudar G Bayer AS; A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007, 44:483-492. 10.1086/511041 17243049
10. Walley T Mantgani A: The UK General Practice Research Database. Lancet 1997, 350:1097-1099. 10.1016/S0140-6736(97)04248-7 10213569
11. Van Staa TP Abenhaim L: The quality of information recorded on a UK database of primary care records: A study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 1994, 3:15-21. 10.1002/pds.2630030106
12. Ruigomez A Johansson S Wallander MA Garcia Rodriguez LA: Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc Disord 2005, 5:20. 1185525 16008832 10.1186/ 1471-2261-5-20
13. Schneider-Lindner V Delaney JA Dial S Dascal A Suissa S: Antibacterial drugs and the risk of infection with methicillin resistant Staphylococcus aureus (MRSA) in the community, United Kingdom. Emerg Infect Dis 2007, 13:994-1000. 18214170
14. Dial S Delaney JA Schneider V Suissa S: Proton pump inhibitor use and the risk of treated Clostridium difficile associated disease in the community. CMAJ 2006, 175:745-748. 1569908 17001054
15. Card TR Solaymani-Dodaran M Hubbard R Logan RF West J: Is an internal comparison better than using national data when estimating mortality in longitudinal studies? J Epidemiol Community Health 2006, 60:819-821. 10.1136/jech.2005.041202 16905729
16. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 1972, 34:187-220.
17. Touloumi G Pocock SJ Babiker AG Darbyshire JH; Impact of missing data due to selective dropouts in cohort studies and clinical trials. Epidemiology 2002, 13:347-355. 10.1097/00001648-200205000-00017 11964938
18. Wyllie DH Crook DW Peto TE: Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: Cohort study. BMJ 2006, 333:281. 1526943 16798756 10.1136/bmj.38834.421713.2F
19. Guilarde AO Turchi MD Martelli CM Primo MG: Staphylococcus aureus bacteraemia: Incidence, risk factors and predictors for death in a Brazilian teaching hospital. J Hosp Infect 2006, 63:330-336. 10.1016/ j.jhin.2006.02.011 16713018
20. National Statistics Deaths: Age and sex, numbers and rates, 1976 onwards (England and Wales): Population Trends 130 http://www.statistics.gov.uk/ STATBASE/ssdataset.asp?vlnk=9552
21. Kerttula AM Lyytikäinen O Salmenlinna S Vuopio-Varkila J: Changing epidemiology of methicillin-resistant Staphylococcus aureus in Finland. J Hosp Infect 2004, 58:109-114. 10.1016/j.jhin.2004.05.019 15474181
22. Micek ST Dunne M Kollef MH: Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: Importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005, 128:2732-2738. 10.1378/chest.128.4.2732 16236949
23. Moran GJ Krishnadasan A Gorwitz RJ Fosheim GE McDougal LK Carey RB Talan DA; EMERGEncy ID Net Study Group Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674. 10.1056/NEJMoa055356 16914702
24. Lo WT Lin WJ Tseng MH Lu JJ Chu ML Wang CC: Nasal carriage of a single clone of community-acquired methicillin-resistant Staphylococcus aureus among kindergarten attendees in northern Taiwan. BMC Infect Dis 2007, 7:51. 1906787 17543109 10.1186/1471-2334-7-51
25. Moodie EM Richardson TS Stephens DA: Demystifying optimal dynamic treatment regimes. Biometrics 2007, 63:447-455. 10.1111/ j.1541-0420.2006.00686.x 17688497
26. Greenland S: Basic methods for sensitivity analysis of biases. Int J Epidemiol 1996, 25:1107-1116. 10.1093/ije/25.6.1107-a 9027513
27. Schneeweiss S: Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006, 15:291-303. 10.1002/ pds.1200 16447304
28. Benedetti A Abrahamowicz M: Using generalized additive models to reduce residual confounding. Stat Med 2004, 23:3781-3801. 10.1002/sim.2073 15580601
29. McCandless LC Gustafson P Levy A: Bayesian sensitivity analysis for unmeasured confounding in observational studies. Stat Med 2007, 26:2331-2347. 10.1002/sim.2711 16998821
30. Suissa S: Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007, 16:241-249. 10.1002/pds.1357 17252614
31. Rothman KJ Greenland S: Modern Epidemiology Philadelphia, PA: Lippincott Williams & Wilkins 2 1998 125
32. Suissa S Garbe E Primer: Administrative health databases in observational studies of drug effects - advantages and disadvantages Nat Clin Pract Rheumatol 2007 3 725 732 10.1038/ncprheum0652 18037932